



Cellectricon Receives Milestone Order for Cellaxess®HT, the World's First High Throughput RNAi Screening System.

Gothenburg, Sweden, November 12, 2008: Cellectricon, a leading provider of advanced screening solutions for drug discovery, has today received its most significant and largest single order to date. The order includes three Cellaxess®HT systems and the customer is a leading US biotech firm.

“An order of this magnitude proves the system’s unique features and value, and validates Cellectricon’s strategy to bring state-of-the-art products for drug discovery and research to the market through world-class customer collaborations.” says Jonas Ohlsson, CEO at Cellectricon. “Cellectricon has developed the Cellaxess®HT system in close collaboration with leading pharmaceutical companies and academic research groups to meet the rapidly growing demand for a true high throughput transfection screening technology, capable of reagent-free delivery of genetic material to biologically relevant cell types”.

Cellaxess®HT is the world’s first fully automated workstation for high throughput RNAi screening on biologically relevant cell types. The system enables reagent free delivery of siRNA and cDNA to a wide range of primary cells and cell lines with excellent efficiency and viability at a throughput of 50, 000 wells per day. Cellaxess®HT is first of its kind on the market and will significantly impact target discovery by providing key functional data in relevant primary human cells.

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology market. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007 the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess®HT System enables high throughput RNAi screening and the Dynaflo®HT System greatly advances ion channel drug discovery.

Contact Details:

Jonas Ohlsson, CEO

Phone: +46 (0)709-73 47 92, E-mail: jonas.ohlsson@cellectricon.com

Susanne Fagerlund, VP Marketing & Communications

Phone: +46 (0)31 760 35 15, E-mail: susanne.fagerlund@cellectricon.com